Vytorin Articles

Whitehouse Station, NJ: It's been awhile since Vytorin has been in the news. The hybrid drug that combines statins Zetia (ezetimibe) and Zocor (simvastatin) into one medication was thought to improve cardiovascular performance through the reduction of plaque accumulations on arterial walls—specifically, atherosclerosis in the carotid artery, located at the neck.

Orlando, FL: According to a recent study from the New England Journal of Medicine, generic B vitamin Niacin was found to be more effective at reducing levels of arterial plaque than Vytorin or Zetia.

Houston, TX: Results of the ARBITER 6-HALTS trial of Zetia (ezetimibe) and Niaspan (niacin) show that Niaspan is more effective than Zetia as a cholesterol treatment. This news has caused some doctors to question whether or not to use Zetia to treat patients with high cholesterol. The results were published along with two editorials in the New England Journal of Medicine on November 15.

Plano, TX: Three years ago, Jim Wiley was taking Lipitor, a statin drug, for elevated cholesterol and tolerating it well. That was when Merck/Schering-Plough introduced Vytorin, a combination drug that contained their proprietary anti-cholesterol drug Zetia and the statin drug Zocor (simvastatin). That's also when things took a turn for the worse—much worse.